Juvenescence28 Sep 2019 11:19
With all the excitement over Leap let’s not forget the rest of the FFWD portfolio. Juvenescence for instance will IPO on the NYSE Q1. I’m confident it will be a unicorn before IPO.
Note a unicorn is an unlisted company with a value in excess of $1 billion.
The business of anti-ageing and rejuvenation.
Bank of America has forecasted that the market will balloon to $610 billion by 2025.
Juvenescence have raised over $165M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully extend human healthspan and lifespan.
Juvenescence's portfolio currently includes Insilico Medicine, a next-generation artificial intelligence company specializing in the application of deep learning to drug discovery and ageing research. Juvenescence AI, a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds; NetraPharma, a joint venture using artificial intelligence to improve clinical trial design; LyGenesis, a company with technology to use a patient's own lymph nodes as bioreactors to grow functioning ectopic organs; and AgeX Therapeutics, a company applying intellectual property related to cell immortality and pluripotency In addition to the above assets, Juvenescence has signed several deals with the Buck Institute for Research on Aging.
Juvenescence is also in advanced negotiations with several other undisclosed research institutions.